Abstract
The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and personalized variety of therapeutic approaches. Within this multifaceted setting, the treatment of anemia represents one of the major challenges as the erythroid line is affected in the majority of (especially lower-risk) MDS patients. 1 Platzbecker U Treatment of MDS. Blood. 2019; 133: 1096-1107 Crossref PubMed Scopus (66) Google Scholar The aim of therapy in this population is to improve anemia, decrease transfusion needs, enhance quality of life, attempt to prolong overall survival, and to reduce the risk of progression. 2 Scalzulli E Pepe S Colafigli G Breccia M Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. Blood Rev. 2020; Crossref Scopus (4) Google Scholar Over the past decade, the understanding of MDS pathophysiology has significantly improved and thereby opened new opportunities for more targeted research approaches, biomarkers, and individualized treatment options. 3 Bewersdorf JP Zeidan AM Evolving therapies for lower-risk myelodysplastic syndromes. Ann Hematol. 2020; Crossref PubMed Scopus (12) Google Scholar This abstract provides a short overview of the current therapeutic landscape in MDS-based anemia and some of the emerging therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
